Soleno Therapeutics Valuation
| SLNO Stock | USD 58.34 1.12 1.96% |
At this time, the company appears to be overvalued. Soleno Therapeutics has a current Real Value of $46.3 per share. The regular price of the company is $58.34. Our model measures the value of Soleno Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 96.96 %, shares outstanding of 43.12 M, and Return On Equity of -0.91 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Soleno Therapeutics' valuation include:
Price Book 9.3207 | Enterprise Value 2.2 B | Enterprise Value Ebitda 0.0233 |
Overvalued
Today
Please note that Soleno Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Soleno Therapeutics is based on 3 months time horizon. Increasing Soleno Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Soleno Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Soleno Stock. However, Soleno Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 58.34 | Real 46.3 | Target 37.0 | Hype 57.97 |
The intrinsic value of Soleno Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Soleno Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Soleno Therapeutics helps investors to forecast how Soleno stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Soleno Therapeutics more accurately as focusing exclusively on Soleno Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Soleno Therapeutics' intrinsic value based on its ongoing forecasts of Soleno Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Soleno Therapeutics' closest peers.
Soleno Therapeutics Cash |
|
Soleno Valuation Trend
Knowing Soleno Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Soleno Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Soleno Therapeutics Total Value Analysis
Soleno Therapeutics is at this time estimated to have valuation of 2.21 B with market capitalization of 2.47 B, debt of 403 K, and cash on hands of 24.07 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Soleno Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.21 B | 2.47 B | 403 K | 24.07 M |
Soleno Therapeutics Asset Utilization
One of the ways to look at asset utilization of Soleno is to check how much profit was generated for every dollar of assets it reports. Soleno Therapeutics has a negative utilization of assets of -0.48 %, losing $0.004805 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Soleno Therapeutics shows how discouraging it operates for each dollar spent on its assets.Soleno Therapeutics Ownership Allocation
The majority of Soleno Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Soleno Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Soleno Therapeutics. Please pay attention to any change in the institutional holdings of Soleno Therapeutics as this could imply that something significant has changed or is about to change at the company.Soleno Therapeutics Profitability Analysis
Net Loss for the year was (38.99 M) with profit before overhead, payroll, taxes, and interest of 0.About Soleno Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Soleno Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Soleno Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Soleno Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Soleno Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Soleno Therapeutics. We calculate exposure to Soleno Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Soleno Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -2 M | -2.1 M | |
| Pretax Profit Margin | 0.01 | 0.01 | |
| Operating Profit Margin | 0.01 | 0.01 | |
| Net Profit Margin | 0.01 | 0.01 | |
| Gross Profit Margin | 0.90 | 0.95 |
Soleno Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 16.5 M |
Soleno Therapeutics Current Valuation Indicators
Soleno Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Soleno Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Soleno Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Soleno Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Soleno Therapeutics' worth.When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Return On Assets (0.48) | Return On Equity (0.91) |
The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.